Appropriate infliximab infusion dosage and monitoring: Results of a panel meeting of rheumatologists, dermatologists and gastroenterologists

British Journal of Clinical Pharmacology

Volumn 71, Issue 1, 2011, Pages 7-19

  De Vries, Hilbert S ^a   Van Oijen, Martijn G H ^a   Driessen, Rieke J B ^a   De Jong, Elke M G J ^a   Creemers, Marjonne C W ^a   Kievit, Wietske ^a   De Jong, Dirk J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Ankylosing spondylitis; Guidelines; Inflammatory bowel disease; Infliximab; Psoriasis; Rheumatoid arthritis

Indexed keywords

AZATHIOPRINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ANAPHYLACTIC SHOCK; ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CROHN DISEASE; DERMATOLOGY; DIZZINESS; DRUG INDICATION; DRUG INFUSION; DRUG MONITORING; DYSPNEA; ENTERITIS; FATIGUE; FLUSHING; GASTROENTEROLOGY; HUMAN; HYPERTENSION; HYPOTENSION; MEDICAL SPECIALIST; MYALGIA; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RASH; RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SIDE EFFECT; THORAX PAIN; VITAL SIGN;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS; CHILD; DRUG MONITORING; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERNATIONAL COOPERATION; SKIN DISEASES; TREATMENT OUTCOME; VITAL SIGNS;

EID: 78650006702     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03760.x     Document Type: Article

References (62)

1. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-73.
2. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006; 355: 704-12.
3. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-34.
4. Clark M, Colombel JF, Feagan BC, Fedorak KN, Hanauer SB, Kamm MA, Mayer L, Regueiro C, Rutgeerts P, Sandborn WJ, Sands BE, Schreiber S, Targan S, Travis S, Vermeire S. American Gastroenterological Association Consensus Development Conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007; 133: 312-39.
5. Lichtenstein GR, Yan SK, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862-9.
6. Travis SPL, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55: i16-i35.
7. Hommes DW, Oldenburg B, Van Bodegraven AA, Van Hogezand RA, De Jong DJ, Romberg-Camps MJL, Van Der Woude J, Dijkstra G. Guidelines for treatment with infliximab for Crohn's disease. Neth J Med 2006; 64: 219-29.
8. Panaccione R, Fedorak RN, Aumais G, Bernstein CN, Bitton A, Croitoru K, Enns R, Feagan B, Fishman M, Greenberg G, Griffiths A, Marshall JK, Rasul I, Sadowski D, Seidman E, Steinhart H, Sutherland L, Walli E, Wild G, Williams CN, Zachos M. Canadian Association of Gastroenterology clinical practice guidelines: the use of infliximab in Crohn's disease. Can J Gastroenterol 2004; 18: 503-8.
9. Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Burmester GR, Braun J, Emery P, Winthrop K, Bresnihan B, De Benedetti F, Dörner T, Gibofsky A, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008; 67: 2-25.
10. Prevoo MLL, Vanthof MA, Kuper HH, Vanleeuwen MA, Vandeputte LBA, Vanriel PLCM. Modified disease-activity scores that include 28-joint counts - development and validation in a prospective longitudinal-study of patients with rheumatoid-arthritis. Arthritis Rheum 1995; 38: 44-8.
11. Dillon A, on behalf of the National Institute for Health and Clinical Excellence. Adalimumab, etanercept and infliximab for the treatment of Rheumatoid arthritis. October 2007. Available at (last accessed 17 August 2010).
12. Medicijnen: Het toepassen van TNF blokkade in de behandeling van reumatoide arthritis. November 2003. Available at (last accessed 17 August 2010).
13. Fautrel B, Pham T, Mouterde G, Le Loët X, Goupille P, Guillemin F, Ravaud P, Cantagrel A, Dougados M, Puéchal X, Sibilia J, Soubrier M, Mariette X, Combe B. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine 2007; 74: 627-37.
14. Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 2007; 17: 451-8.
15. Soderlin MK, Geborek P. Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden. Ann Rheum Dis 2008; 67: 37-42.
16. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNF alpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005; 44: 157-63.
17. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE. American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84.
18. Braun J, Davis J, Dougados M, Sieper J, Van Der Linden S, Van Der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65: 316-20.
19. Van der Horst-Bruinsma IE, Franssen MJAM, Oostveen JCM, Van Denderen JC, Leijsma MK, De Sonnaville PBJ, Nurmohamed MT, Van Der Linden Sj. Richtlijn voor de diagnostiek en behandeling van spondylitis ankylopoetica. 2009. Available at (last accessed 17 August 2010).
20. Vanderlinden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis - A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
21. Keat A, Barkham N, Bhalla A, Gaffney K, Marzo-Ortega H, Paul S, Rogers F, Somerville M, Sturrock R, Wordsworth P. BSR Standards, Guidelines and Audit Working group. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology 2005; 44: 939-47.
22. Pham T, Fautrel B, Dernis E, Goupille P, Guillemin F, Le Loët X, Ravaud P, Claudepierre P, Miceli-Richard C, De Bandt M, Breban M, Maillefert JF, Masson C, Saraux A, Schaeverbeke T, Wendling D, Mariette X, Combe B. Club Rhumatismes et Inflammation (CRI/SFR). Recommendations of the French Society for Rheumatology regarding TNF alpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine 2007; 74: 638-46.
23. Dillon A, on behalf of the National Institute for Health and Clinical Excellence. Adalimumab, etanercept and infliximab for ankylosing spondylitis. May 2008. Available at (last accessed 17 August 2010).
24. Dillon A, on behalf of the National Institute for Health and Clinical Excellence. Etanercept and infliximab for the treatment of adults with psoriatric arthritis. 2007. Available at (last accessed 17 August 2010).
25. Reich K, Griffiths C, Barker J, Chimenti S, Daudén E, Giannetti A, Gniadecki R, Katsambas A, Langley R, Mrowietz U, Ogilvie A, Ortonne JP, Reider N, Saurat JH. Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. Dermatology 2008; 217: 268-75.
26. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD. British Association of Dermatologists. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153: 486-97.
27. Nederlandse vereniging voor dermatologie en venereologie. Het toepassen van biologicals in de behandeling van patiënten met plaque psoriasis. December 2004. Available at (last accessed 17 August 2010).
28. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN. Randomized double-blind comparison of chimeric monoclonal-antibody to tumor-necrosis-factor-alpha (Ca2) versus placebo in rheumatoid-arthritis. Lancet 1994; 344: 1105-10.
29. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
30. Maini RN, Elliot MJ, Longfox A, Feldmann M, Kalden JR, Antonio C, Smolen JS, Leeb B, Breedveld FC, MacFarlane JD, Bijl H, Woody JN. Clinical-response of rheumatoid arthritis (Ra) to anti-TNF-alpha (Ca2) monoclonal antibody (Mab) is related to administered dose and persistence of circulating antibody. Arthritis Rheum 1995; 38: 200.
31. Targan SR, Hanauer SB, Van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997; 337: 1029-35.
32. McCabe RP, Woody J, Van Deventer S, Targan SR, Mayer L, Van Hogezand R, Rutgeerts P, Hanauer SB, Podolsky D, Elson CO. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease. Gastroenterology 1996; 110: A962.
33. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000; 42: 829-30.
34. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-7.
35. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
36. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis - Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-50.
37. Baert F, Noman M, Vermeire S, Van Assche G, Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
38. Wolbink GJ, Vis M, Lems W, Voskuyl AE, De Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 711-5.
39. De Vries MK, Wolbink GJ, Stapel SO, De Groot ER, Dijkmans BA, Aarden LA, Van Der Horst-Bruinsma IE. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. Ann Rheum Dis 2007; 66: 133-4.
40. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, Plevy S. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315-24.
41. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 2002; 97: 2962-72.
42. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, De Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
43. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31.
44. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007; 46: 645-60.
45. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54.
46. St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, Keystone EC. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis - Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1451-9.
47. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-54.
48. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE. EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-74.
49. De Vries MK, Wolbink GJ, Stapel SO, De Vrieze H, Van Denderen JC, Dijkmans BA, Aarden LA, Van Der Horst-Bruinsma IE. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 2007; 66: 1252-4.
50. Mulleman D, Méric JC, Paintaud G, Ducourau E, Magdelaine-Beuzelin C, Valat JP, Goupille P. Centre National de la Recherche Scientifique UMR 6239 GICC. Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis. Arthritis Res Ther 2009; 11: R178.
51. Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, Paintaud G. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008; 30: 523-9.
52. Flendrie M, Creemers MCW, Van Riel PLCM. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. Rheumatology 2007; 46: 146-9.
53. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-30.
54. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, Henckaerts L, Van Assche G, Vermeire S, Rutgeerts P. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501-8.
55. De Vries HS, Van Oijen MGH, Van Hoven-van Loo KEJ, De Jong DJ. Monitoring vital signs during infusion with infliximab does neither indicate nor predict development of acute infusion reactions. J Clin Gastroenterol 2009; 43: 387-8.
56. Lopez-Olivo MA, Kallen MA, Ortiz Z, Skidmore B, Suarez-Almazor ME. Quality appraisal of clinical practice guidelines and consensus statements on the use of biologic agents in rheumatoid arthritis: a systematic review. Arthritis Rheum-Arthritis Care Res 2008; 59: 1625-38.
57. Maksymowych WP, Inman RD, Gladman D, Thomson G, Stone M, Karsh J, Russell AS. Spondyloarthritis Research Consortium of Canada (SPARCC). Canadian Rheumatology Association consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis. J Rheumatol 2003; 30: 1356-63.
58. Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, De La Brassinne M, Ferrandiz C, Griffiths C, Katsambas A, Kragballe K, Lynde C, Menter A, Ortonne JP, Papp K, Prinz J, Rzany B, Ronnevig J, Saurat JH, Stahle M, Stengel FM, Van De Kerkhof P, Voorhees J. Biological therapies in the systemic management of psoriasis: international consensus conference. Br J Dermatol 2004; 151: 3-17.
59. Dillon A, on behalf of the National Institute for Health and Clinical Excellence. Infliximab for the treatment of adults with psoriasis. January 2008. Available at (last accessed 17 August 2010).
60. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A. Guidelines of care for the management of psoriasis and psoriatic arthritis - Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008; 58: 851-64.
61. Centocor Product Information. 2009. Availalble at (last accessed 17 August 2010).
62. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, Ghrayeb J. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443-1453.